Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its news flow reflects both its operating performance and corporate developments. Company announcements describe technologies that prioritize preservation and restoration of the patient’s own anatomy and leverage the natural healing response while minimizing long-term exposure to permanent synthetic materials.
News updates for TELA stock frequently include quarterly financial results, where the company reports revenue, gross profit, operating expenses, and net loss, along with commentary on demand for its OviTex and OviTex PRS reinforced tissue matrix products. These releases often discuss factors driving revenue, such as increased unit sales, new customers, international sales, and new product configurations, as well as changes in operating expenses and loss from operations.
Investors can also expect capital markets and financing news, including announcements of credit facilities, registered direct offerings of common stock and pre-funded warrants, and the issuance of warrants in connection with debt agreements. Such updates provide insight into TELA Bio’s liquidity, borrowing arrangements, and intended use of proceeds for sales and marketing, research and development, and other corporate purposes.
Another category of TELA Bio news involves corporate governance and leadership changes, such as appointments of new independent directors with experience in healthcare equity research and executive nursing leadership, as well as board resignations. The company also issues releases about participation in healthcare conferences and inducement grants of restricted stock units and stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
By following TELA Bio’s news feed, readers gain timely visibility into the company’s financial performance, product demand trends in soft-tissue reconstruction, capital-raising activities, and changes in board composition and employee equity incentives.
TELA Bio (NASDAQ: TELA), a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions, has announced its plan to report second quarter 2024 financial results on Monday, August 12, 2024. The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the financial results and provide a corporate update.
Investors interested in participating in the conference call are required to register online at least a day in advance or a minimum of 15 minutes before the call starts. A live webcast and replay of the event will be accessible through the Events & Presentations page in the investor section of TELA Bio's website.
On June 4, 2024, TELA Bio, a medical technology company specializing in soft-tissue reconstruction solutions, announced the appointment of Jeffrey Blizard to its Board of Directors. Blizard is currently the Global Head of Surgical Sales at Abiomed, a medical device company within Johnson & Johnson's MedTech segment. TELA Bio's CEO, Antony Koblish, emphasized Blizard's extensive sales leadership and experience as important to enhancing their sales force. Blizard expressed enthusiasm about joining during a period of significant growth and confident in his ability to contribute to TELA's success.
TELE Bio (NASDAQ: TELA) has appointed Greg Firestone as its new Chief Commercial Officer, effective May 20, 2024. Mr. Firestone, who has been with the company since 2017, will now oversee commercial operations, including key product launches, sales team training, market development, and strategic initiatives. His extensive experience includes executive roles in the healthcare sector and founding multiple companies. The appointment is viewed as a strategic move to enhance market share and operational efficiency as the company aims for strong year-end performance.
TELA Bio, Inc. announced the approval of inducement grants of restricted stock units to newly-hired employees. The grants cover 20,250 shares of common stock and were approved on May 6, 2024. The restricted stock units will vest over four years, contingent on the employees' continued service with TELA Bio.
TELA Bio, Inc. reported strong financial results for Q1 2024, with revenue reaching $16.6 million, a 39% increase from the same period in 2023. The company achieved its 13th consecutive quarter of over 35% year-over-year growth and increased full-year revenue guidance to $74.5 million to $76.5 million. Gross profit was $11.3 million, operating expenses rose to $23.7 million, resulting in a loss from operations of $4.8 million. However, a one-time gain of $7.6 million from the sale of assets to MiMedx helped offset the loss, leading to a net loss of $5.7 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.